Objective To dynamically monitor the serum levels of squamous cell carcinoma antigen(SCC-AG),cytokeratin 19 serum fragment 21-1(CYFRA21-1),and human epididymal protein 4(HE4)in patients with non-small-cell lung carcinoma and analyze its clinical application value.Methods From January of 2021 to September of 2023,108 non-small-cell lung carcinoma patients were selected as the study group and 108 benign pulmonary disease patients as the control group.The serum levels of SCC-Ag,CYFRA21-1,and HE4 were measured in patients with benign pulmonary disease at admission and in patients with non-small-cell lung carcinoma disease at admission,and compared with those in patients with different treatment courses in the study group.Results The serum levels of SCC-Ag,CYFRA21-1,and HE4 in the study group were significantly higher than those in the control group(P＜0.05),and the serum levels of SCC-Ag,CYFRA21-1,and HE4 in the study group were 1 day after operation＞7 days after operation＞30 days after operation＞90 days after operation.The area under the curve(AUC)of SCC-Ag,CYFRA21-1,and HE4 for the diagnosis of non-small-cell lung carcinoma was 0.923,and sensitivity and specificity were 88.0％and 83.3％.Conclusion The serum levels of SCC-Ag,CYFRA21-1,and HE4 were significantly increased in patients with non-small-cell lung carcinoma and significantly decreased in different postoperative periods,it was found that the combined detection of the three non-small-cell lung carcinoma could improve the diagnostic efficiency of lung cancer and provide a new method for early diagnosis and therapeutic evaluation of lung cancer.
维普
万方数据